CanBas
CanBas Co., Ltd. (株式会社キャンバス) is a Japanese clinical-stage biopharmaceutical company developing peptide-based anticancer agents with reduced side effects, led by CBP501 (Phase 2/3) for third-line metastatic pancreatic cancer in triple-combination therapy, with a secondary asset licensed to Stemline/Menarini.
- Company typePublic
- Founded2000
- HeadquartersNumazu, Japan
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CanBas does
CanBas Co., Ltd. (株式会社キャンバス) is a Japan-based clinical-stage biopharmaceutical company founded in 2000 and listed on the Tokyo Stock Exchange Growth Market (ticker: 4575). The company is headquartered in Numazu, Shizuoka, and operates with a lean team of 11-50 employees focused exclusively on discovering and developing anticancer agents with reduced side-effect profiles. CanBas's lead clinical asset is CBP501, a peptide-based immunogenic cell death inducer designed for triple-combination therapy with cisplatin and nivolumab in third-line metastatic pancreatic cancer; Phase 2 results demonstrated median overall survival of 6.3 months versus approximately 3 months for standard of care, supporting a 2027 commercial launch target. The company's second clinical asset, CBS9106 (SL-801), is a reversible XPO1 inhibitor licensed to Stemline Therapeutics (now part of Menarini Group) for global development, with the program recently pivoted from hematologic malignancies to solid tumor indications. Preclinical pipeline includes next-generation peptides (CBP-A08, CBT005), CBP-A and CBP-B series candidates, and an IDO/TDO inhibitor under joint research with Shizuoka University of Technology.
CanBas monetizes primarily through licensing royalties and technical advisory fees from its CBS9106 partnership with Stemline/Menarini, generating approximately 27-55 million yen per quarter. The company has no product sales revenue and is funded via public equity markets, having raised approximately 4.4 billion yen across two financing rounds in September 2021 (17th share subscription rights and 4th convertible bonds) and November 2022 (full exercise of 17th share subscription rights). GTM is sales-led with a focus on out-licensing pipeline assets to pharmaceutical partners for global commercialization while advancing proprietary candidates through clinical milestones. Customer segments split between pharmaceutical partners (licensing/collaboration) and, post-approval, oncology patients — particularly those with pancreatic adenocarcinoma (approximately 50,000 new US cases annually, with 10,000+ eligible for third-line treatment).
The company's competitive position is anchored by FDA Orphan Drug Designation for CBP501 (granted January 2023, providing up to 7 years of US market exclusivity post-approval), proprietary use patent WO2014/207556 (extended through 2028), and a proprietary cell cycle phenotype screening platform that originated CBP501. Key risks include single-asset revenue concentration on CBS9106 advisory fees, European Phase 3 trial delays stemming from EU manufacturing compliance issues (November 2024), pre-commercial revenue profile with cumulative net losses, and the binary nature of clinical-stage biotech execution on the lead Phase 3 program.
CanBas firmographics
Firmographics- Name
- CanBas
- Legal name
- 株式会社キャンバス
- Website
- https://canbas.co.jp
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CanBas Co., Ltd. (株式会社キャンバス) is a Japanese clinical-stage biopharmaceutical company developing peptide-based anticancer agents with reduced side effects, led by CBP501 (Phase 2/3) for third-line metastatic pancreatic cancer in triple-combination therapy, with a secondary asset licensed to Stemline/Menarini.
- Ownership category
- akta.pro rank
CanBas industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)
- akta.pro secondary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where CanBas is headquartered
LocationHeadquarters
- HQ city
- Numazu
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
CanBas business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel
Revenue model
- 技術アドバイザリーフィー収益: Stemline社とのCBS9106（SL-801）ライセンス契約に基づき、技術アドバイザリー業務に対する報酬として四半期ごとに収益を受領している。契約開始から4年間のほぼ安定的な収益源。
- 抗がん剤上市による製品売上手柄: 抗がん剤の承認・上市が実現した場合、薬剤販売による収益を見込む。上市目標は2027年。
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
CanBas product offering
Product offeringCore offering
CanBas is a drug-discovery biotech company that researches and develops anticancer drugs with fewer side effects, leveraging a proprietary cell cycle phenotype screening method. Its lead clinical-stage candidate CBP501 is a peptide-based immune activator being evaluated in Phase 2 trials as a triple-combination therapy (CBP501 + cisplatin + nivolumab) for metastatic pancreatic cancer. A second clinical asset, CBS9106 (reversible XPO1 inhibitor), has been out-licensed to Stemline/Menarini for solid tumor development, with additional preclinical candidates in CBP-A, CBP-B, and IDO/TDO inhibitor series.
Product overview
CanBas is a drug-discovery biotech company developing a pipeline of anticancer agents led by two clinical-stage candidates. CBP501 (immune activator) is in Phase 2 clinical trials in the US and Europe for third-line metastatic pancreatic cancer, administered as a triple-combination therapy (CBP501 + cisplatin + nivolumab). CBS9106 (reversible XPO1 inhibitor) is in solid tumor development following a shift away from hematologic malignancies. The preclinical pipeline includes the CBP-A series (next-generation peptides related to CBP501), CBP-B series (immune suppression reversal mechanism), an IDO/TDO inhibitor, and additional NEXT-stage projects in early research.
Differentiator
Problem solved
Functional benefit
Brands
- CBP501 (免疫着火剤): Lead pipeline compound - an immune stimulant (immunological igniter) developed by CanBas, used in combination with cisplatin and nivolumab for cancer treatment.
- CBS9106 (可逆的XPO1阻害剤)
Products and services
- CBP501 (Immune Activator / Immunological Ignition Agent) Peptide-based anticancer agent functioning as an immune activator (immunological ignition agent). CBP501 enhances the anticancer effects of platinum-based drugs by promoting their influx into cancer cells through direct contact with calmodulin, and activates anticancer immunity via effects on macrophages in the tumor microenvironment. Administered as triple-combination therapy with cisplatin and nivolumab for third-line metastatic pancreatic cancer. In Phase 2 clinical trials with FDA Orphan Drug Designation.
- CBS9106 (Reversible XPO1 Inhibitor, development code SL-801) Reversible XPO1 (Exportin 1) inhibitor low-molecular-weight compound developed for solid tumors. Originally investigated for hematologic malignancies (multiple myeloma) under Stemline Therapeutics, with development subsequently shifted to solid tumor indications including colorectal cancer, KRAS-mutant cancers, renal cell carcinoma, and p53-associated cancers in combination with other anticancer agents. Out-licensed globally to Stemline/Menarini.
- CBP-A Series Peptides (Preclinical Pipeline) Peptide-type anticancer agent candidates belonging to the same lineage as the original peptide TAT-S216 and its optimized derivative CBP501. Development candidate selection is ongoing.
- CBP-B Series Peptides (Preclinical Pipeline)
- IDO/TDO Inhibitor
- CBP-A08 (Next-Generation Peptide Anticancer Agent)
- CBT005 (Next-Generation Immune Activation Anticancer Agent)
Quantifiable outcome
- 転移性膵臓腺がん3次治療における全生存期間中央値6.3ヶ月（3剤併用群1群）— 現行治療約3ヶ月の約2.1倍
- +2 more outcomes
Companies that use CanBas
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles3 records
CanBas technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CanBas partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Stemline Therapeutics社（Menarini Group傘下）coreCBS9106（開発コードSL-801）の全世界における独占的ライセンス契約を締結。Stemline社は进行固形癌対象臨床第1相試験を実施し、ESMO2020での発表後は血液がんから固形がん対象开发にシフト。Menarini GroupによるStemline買収後も開発は継続される。同社로부터技術アドバイザリーフィーを四半期ごとに受領（27〜55百万円/年程度）。
- NEDO（国立研究開発法人新エネルギー・産業技術総合開発機構）minorCBP501の製造法改良に関する補助事业を実施。承認されても大丈夫な製造法を既に確立するに至った。
- 静岡県立大学minorIDO/TDO阻害剂の共同研究を実施。COVID-19重症患者におけるサイトカインストーム抑制作用の研究にも関連する。
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
CanBas competitors and assessment
Company assessmentOthers
- Menarini Group: Italian pharma group that acquired Stemline Therapeutics (the licensee of CanBas's CBS9106/SL-801). Comparable as the indirect commercial partner and existing royalty payer for CanBas's out-licensed XPO1 inhibitor asset.
Direct peers
- NanoCarrier: Japanese oncology-focused biotech developing polymeric micelle drug delivery for cancer. Comparable as a small Japanese pre-commercial oncology company pursuing novel mechanisms with TSE listing and similar scale.
- PeptiDream: Japanese peptide-based drug discovery biotech listed on TSE Prime. Directly comparable to CanBas in using proprietary peptide platforms to develop constrained/peptidic therapeutics, including oncology candidates, with a similar small-cap, Japan-listed profile.
Emerging players
- Compugen: Clinical-stage immuno-oncology company developing novel computational-predicted drug targets for combinations with checkpoint inhibitors. Comparable as a clinical developer focused on immune-modulating combinations in oncology.
- Mirati Therapeutics: Clinical-stage oncology biotech focused on targeted immuno-oncology combinations (KRAS inhibitors). Comparable as a smaller-scale oncology combination-therapy developer whose pivot through Phase 2/3 mirrors CanBas's risk profile.
Broad incumbents
- Taiho Pharmaceutical: Japan's leading oncology-focused pharmaceutical company with established anticancer franchise (Lonsurf, Teysuno). Comparable as the dominant Japanese oncology player that new immune-oncology assets like CBP501 would ultimately compete against or partner with.
- Ono Pharmaceutical: Japan-based pharma that developed and commercializes nivolumab (Opdivo), the checkpoint inhibitor used in CanBas's triple-combination regimen. Highly comparable strategic partner/customer as the IO backbone supplier for CBP501 therapy.
- Daiichi Sankyo: Major Japanese pharmaceutical company with significant oncology pipeline including ADC franchise (Enhertu). Comparable as a large Japanese oncology incumbent that could acquire or partner with promising Japanese biotechs in oncology.
- Chugai Pharmaceutical: Japanese pharma leader with major oncology portfolio and biotech R&D heritage (Roche subsidiary). Comparable as the benchmark large-cap Japanese oncology innovator, useful for valuation and partnership framework reference.
- Astellas Pharma: Large Japanese global pharmaceutical company with oncology in its portfolio (Xtandi, Padcev). Comparable as an established Japanese oncology player that could be a potential acquirer of CanBas or commercial partner for pancreatic assets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
CanBas social profiles
Digital presenceCanBas compliance and trust
Trust signalCompliance1 record
CanBas financial estimates
Financial estimateRevenue estimate
Valuation estimate
CanBas leadership team
Management profileNumber of profiles
Profiles1 record
CanBas funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CanBas M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CanBas
What does CanBas do?
CanBas is a drug-discovery biotech company that researches and develops anticancer drugs with fewer side effects, leveraging a proprietary cell cycle phenotype screening method. Its lead clinical-stage candidate CBP501 is a peptide-based immune activator being evaluated in Phase 2 trials as a triple-combination therapy (CBP501 + cisplatin + nivolumab) for metastatic pancreatic cancer. A second clinical asset, CBS9106 (reversible XPO1 inhibitor), has been out-licensed to Stemline/Menarini for solid tumor development, with additional preclinical candidates in CBP-A, CBP-B, and IDO/TDO inhibitor series.
Is CanBas a public or private company?
CanBas is a public company. It is classified as public and is currently operating.
When was CanBas founded?
CanBas was founded in 2000. It employs 11 to 50 people.
Where is CanBas based?
CanBas is headquartered in Numazu, Japan, in the Asia region.
How does CanBas make money?
Two revenue lines are on record. 技術アドバイザリーフィー収益 is the primary driver. The others are 抗がん剤上市による製品売上手柄.
Who are CanBas's main competitors?
Menarini Group is listed as an others. Direct peers are NanoCarrier and PeptiDream. Emerging players are Compugen and Mirati Therapeutics. Broad incumbents are Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, Chugai Pharmaceutical and Astellas Pharma.
Does CanBas have an API?
No public API is recorded for CanBas.
What industry is CanBas in?
CanBas's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541714 and its SIC code is 2834.